Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes. Phenotype 1 is a moderate (but not clinically severe) drop in platelet coun...

Descripción completa

Detalles Bibliográficos
Autores principales: Slingsby, Martina H. Lundberg, Vijey, Prakrith, Tsai, I-Ting, Roweth, Harvey, Couldwell, Genevieve, Wilkie, Adrian R., Gaus, Hans, Goolsby, Jazana M., Okazaki, Ross, Terkovich, Brooke E., Semple, John W., Thon, Jonathan N., Henry, Scott P., Narayanan, Padmakumar, Italiano, Joseph E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804562/
https://www.ncbi.nlm.nih.gov/pubmed/33567808
http://dx.doi.org/10.3324/haematol.2020.260059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804562/
https://www.ncbi.nlm.nih.gov/pubmed/33567808
http://dx.doi.org/10.3324/haematol.2020.260059

Ejemplares similares